Avalo Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• AVTX-002 · Diabetes
  AVTX-002 is a small molecule that targets the SGLT2 receptor.
• AVTX-009 Regimen 1
• AVTX-009 Regimen 2 · unknown
  AVTX-009 Regimen 2 is a small molecule that targets the molecular target.
• CERC-301 · Autoimmune diseases, Oncology
  CERC-301 is a monoclonal antibody targeting CD28 to modulate T-cell activation.
• FP01

Phase 1 pipeline

• AEVI-007

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Avalo Therapeutics, Inc. portfolio CI brief
• Avalo Therapeutics, Inc. pipeline updates RSS